Dansk Selskab for Almen Medicin logoDansk Selskab for Almen Medicin logo
Klinisk vejledning

Publiseret: 2007

Blødningsforstyrrelser hos kvinder i almen praksis

OBS: Vejledning over 5 år

DSAM tager forbehold for, at der kan være nye retningslinjer/ny evidens på området. Vi har dog valgt at lade vejledningen være aktiv, da der stadig er en del brugbar information i den.


  1. Shaw R, Soutter W, Stanton S. Gynaecology. Second Edition. Churchill Livingstone; 1997.

  2. Sherman BM, West JH, Korenman SG. The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. J Clin Endocrinol Metab 1976 Apr;42(4):629-36.

  3. Edmonds DK. Menstrual changes in adolescence. Baillieres Clin Obstet Gynaecol 1989 Jun;3(2):329-39.

  4. Roche AF. Secular trends in human growth, maturation, and development. Monogr Soc Res Child Dev 1979;44(3-4):1-120.

  5. Tanner JM. Trend towards earlier menarche in London, Oslo, Copenhagen, the Netherlands and Hungary. Nature 1973 May 11;243(5402):95-6.

  6. Mckinley S, Jeffery S, Thompson B. An investigation of the age at menopause. J Biosoc Sci 1972;4:161-73.

  7. Treloar AE, Boynton RE, Behn BG, Brown BW. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967 Jan;12(1 Pt 2):77-126.

  8. Vollman RF. The menstrual cycle. Major Probl Obstet Gynecol 1977;7:1-193.

  9. Astrup K, Olivarius NF, Moller S, Gottschau A, Karlslund W. Menstrual bleeding patterns in pre- and perimenopausal women: a population-based prospective diary study. Acta Obstet Gynecol Scand 2004 Feb;83(2):197-202.

  10. Munster K, Schmidt L, Helm P. Length and variation in the menstrual cycle – a cross-sectional study from a Danish county. Br J Obstet Gynaecol 1992 May;99(5):422-9.

  11. Shapley M, Jordan K, Croft PR. An epidemiological survey of symptoms of menstrual loss in the community. Br J Gen Pract 2004 May;54(502):359-63.

  12. Research on the Menopause in the 1990s. Report of a WHO Scientific group. Geneva: World Health Organization; 1996. Report No.: 866.

  13. Astrup K, Olivarius NF. Frequency of spontaneously occurring postmenopausal bleeding in the general population. Acta Obstet Gynecol Scand 2004 Feb;83(2):203-7.

  14. Matsumoto S et al. Statistical studies of menstruation: a criticism of the definition of the normal menstruation. Gumma Journal of Medical Science 1962;11:294-318.

  15. Harlow SD, Ephross SA. Epidemiology of menstruation and its relevance to women’s health. Epidemiol Rev 1995;17(2):265-86.

  16. Chimbira TH, Anderson AB, Turnbull A. Relation between measured menstrual blood loss and patient’s subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area. Br J Obstet Gynaecol 1980 Jul;87(7):603-9.

  17. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss--a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45(3):320-51.

  18. Cole SK, Billewicz WZ, Thomson AM. Sources of variation in menstrual blood loss. J Obstet Gynaecol Br Commonw 1971 Oct;78(10):933-9.

  19. Fraser IS, McCarron G, Markham R, Resta T. Blood and total fluid content of menstrual discharge. Obstet Gynecol 1985 Feb;65(2):194-8.

  20. Haynes PJ, Hodgson H, Anderson AB, Turnbull AC. Measurement of menstrual blood loss in patients complaining of menorrhagia. Br J Obstet Gynaecol 1977 Oct;84(10):763-8.

  21. Crosignani PG, Vegetti W. A practical guide to the diagnosis and management of amenorrhoea. Drugs 1996 Nov;52(5):671-81.

  22. Munster K, Helm P, Schmidt L. Secondary amenorrhoea: prevalence and medical contact--a cross-sectional study from a Danish county. Br J Obstet Gynaecol 1992 May;99(5):430-3.

  23. UpToDate. Putting Clinical Information Into Practice. www.uptodate.com  2007.

  24. O´Brien S, Cameron L, Maclean A. Disorders of the Menstrual Cycle. London: RCOG; 2000. p. 346-67.

  25. Balen A, Conway G, Homburg R, Legro R. Polycystic Ovary Syndrome - A Guide to Clinical Management. Taylor & Francis; 2005.

  26. ESHRE Workshop Group. HRU 2003;9:263-74.

  27. Guzick DS. Polycystic ovary syndrome. Obstet Gynecol 2004 Jan;103(1):181-93.

  28. Svendsen PF, Nilas L, Norgaard K, Madsbad S. Polycystisk ovariesyndrom. Nyere patofysiologiske iagttagelser--behandlingsmæssige konsekvenser. Ugeskr Laeger 2005 Aug 22;167(34):3147-51.

  29. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003 Oct 25;327(7421):951-3.

  30. DSOG-guidelines. Polycystisk ovariesyndrom. Første udkast. Sept. 2004. http://www.dsog.dk/files/PCOS/PCOS_guidelineudkast_150804.pdf.  2004.

  31. Allen DG, Correy JF, Marsden DE. Abnormal uterine bleeding and cancer of the genital tract. Aust N Z J Obstet Gynaecol 1990 Feb;30(1):81-3.

  32. Fraser IS, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume. Am J Obstet Gynecol 1984 Aug 1;149(7):788-93.

  33. Rees MC, Chimbira TH, Anderson AB, Turnbull A. Menstrual blood loss: Measurement and clinical correlates. Research and Clinical Forums 4, 69-80. 1989.

  34. Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995 Jun;85(6):977-82.

  35. DSOG-guideline. Blødningsforstyrrelser. 2003: http://www.dsog.dk/bloedningsforstyr/guidelineMenorrhagia150603(w).htm  2007.

  36. Guidelines for the management of heavy menstrual bleedning. The National Health Committee (New Zealand): http://www.nzgg.org.nz/guidelines/dsp_guideline_popup.cfm?&GuidelineID=32 2007. (OBS! Linket er ikke længere aktivt).

  37. Prodigy Guidance Menorrhagia (1998-2005): http://www.prodigy.nhs.uk/ guidance.asp?gt=Menorrhagia 2007. (OBS! Linket er ikke længere aktivt).

  38. National Evidence-Based Clinical Guidelines (RCOG).1998. The initial Managemet of Menorrhagia: http://www.rcog.org.uk/index.asp?PageID=698 2007. (OBS! Linket er ikke længere aktivt).

  39. DSOG-guideline.www.dsog.dk/bloedningsforstyr/gestagenspiralen150603w.htm 2003.

  40. Nye kræfttilfælde. Sundhedsstatistik. http://www.sst.dk/Informatik_og_sundhedsdata/Download_sundhedsstatistik/  Kraeft/Kraeft_2.aspx?lang=da Sundhedsstyrelsen 2007. (OBS! Linket er ikke længere aktivt).

  41. DSOG-guideline.: www.dsog.dk/bloedningsforstyr/Mettrorhagiguideline17juniw.htm 2003.

  42. Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000 Oct 15;89(8):1765-72.

  43. Schacke E, Nilas L. Blødningsforstyrrelser i fertil alder. Rationel Farmakoterapi. 4-4-2002. Institut for Rationel Farmakoterapi.

  44. Damsbo N, Bjerrum P, Bro F, Poulsen E, Wilken-Jensen C. Gynækologi i almen praksis. København: Munksgaard; 2005.

  45. DSOG-guideline. Postmenopausal blødning uden HRT: www.dsog.dk/ bloedningsforstyr/Guidelinepostmenopausal%20uden%20HRT150603w.htm - 58k 2007.

  46. DSOG-guideline. 2003.Postmenopausal blødning hos kvinder uden hormonbehandling: http//www.dsog.dk/bloedningsforstyr/ baggrundpostmenopausalbldning1506.03.htm-33k 2007.

  47. Scottish Intercollegiate Guidelines Network. Investigation of Post-Menopausal Bleeding. 2002: http://www.sign.ac.uk/guidelines/fulltext/61/index.html 2007. (OBS! Linket er ikke længere aktivt).

  48. Granberg S, Ylostalo P, Wikland M, Karlsson B. Endometrial sonographic and histologic findings in women with and without hormonal replacement therapy suffering from postmenopausal bleeding. Maturitas 1997 May;27(1):35-40.

  49. Gredmark T, Kvint S, Havel G, Mattsson LA. Histopathological findings in women with postmenopausal bleeding. Br J Obstet Gynaecol 1995 Feb;102(2):133-6.

  50. Karlsson B, Granberg S, Wikland M, Ylostalo P, Torvid K, Marsal K, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding – a Nordic multicenter study. Am J Obstet Gynecol 1995 May;172(5):1488-94.

  51. DSOG-guidelines. Risiko for hyperplasi eller endometriecarcinom ved blødningsforstyrrelser.2003:  http://www.dsog.dk/bloedningsforstyr/Guideline%20-%20Hyperplasi%2015.  juni%202003%20Fw.htm 2007.

  52. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 2000 Sep 9;356(9233):881-7.

  53. Feldman S, Cook EF, Harlow BL, Berkowitz RS. Predicting endometrial cancer among older women who present with abnormal vaginal bleeding. Gynecol Oncol 1995 Mar;56(3):376-81.

  54. Parazzini F, La VC, Bocciolone L, Franceschi S. The epidemiology of endometrial cancer. Gynecol Oncol 1991 Apr;41(1):1-16.

  55. Clark TJ, Mann CH, Shah N, Khan KS, Song F, Gupta JK. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review. BJOG 2002 Mar;109(3):313-21.

  56. Ferrazzi E, Torri V, Trio D, Zannoni E, Filiberto S, Dordoni D. Sonographic endometrial thickness: a useful test to predict atrophy in patients with postmenopausal bleeding. An Italian multicenter study. Ultrasound Obstet Gynecol 1996 May;7(5):315-21.

  57. Gull B, Carlsson S, Karlsson B, Ylostalo P, Milsom I, Granberg S. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: is it always necessary to perform an endometrial biopsy? Am J Obstet Gynecol 2000 Mar;182(3):509-15.

  58. Akerlund M, Rode A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br J Obstet Gynaecol 1993 Sep;100(9):832-8.

  59. Endrikat J, Muller U, Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 1997 Mar;55(3):131-7.

  60. Endrikat J, Dusterberg B, Ruebig A, Gerlinger C, Strowitzki T. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception 1999 Nov;60(5):269-74.

  61. Halbe HW, de Melo NR, Bahamondes L, Petracco A, Lemgruber M, de Andrade RP, et al. Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene. Eur J Contracept Reprod Health Care 1998 Sep;3(3):113-20.

  62. Serfaty D, Vree ML. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene. Eur J Contracept Reprod Health Care 1998 Dec;3(4):179-89.

  63. Zichella L, Sbrignadello C, Tomassini A, Di LA, Montoneri C, Zarbo G, et al. Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel or 75 microgram gestodene. Adv Contracept 1999;15(3):191-200.

  64. Rosenberg MJ, Waugh MS, Higgins JE. The effect of desogestrel, gestodene, and other factors on spotting and bleeding. Contraception 1996 Feb;53(2):85-90.

  65. Van Vliet HA, Grimes DA, Helmerhorst FM, Schulz KF. Biphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2006;3:CD002032.

  66. Krettek JE, Arkin SI, Chaisilwattana P, Monif GR. Chlamydia trachomatis in patients who used oral contraceptives and had intermenstrual spotting. Obstet Gynecol 1993 May;81(5 ( Pt 1)):728-31.

  67. Bjarnadottir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 2002 Mar;186(3):389-95.

  68. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002 Sep;100(3):585-93.

  69. Audet MC, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 2001 May 9;285(18):2347-54.

  70. Porter C, Rees MC. Bleeding problems and progestogen-only contraception. J Fam Plann Reprod Health Care 2002 Oct;28(4):178-81.

  71. Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. Contraception 1998 Dec;58(6 Suppl):99S-107S.

  72. Johansen JR, Andersen JS, Dupont M, Hindsberger C, Obel EB. Gener og komplikationer efter spiraloplaegning foretaget i almen praksis. Ugeskr Laeger 2004 Sep 6;166(37):3190-4.

  73. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990 Aug;97(8):690-4.

  74. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994 Jan;61(1):70-7.

  75. Barrington JW, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol 1997 May;104(5):614-6.

  76. Gambrell RD, Jr., Bagnell CA, Greenblatt RB. Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: review. Am J Obstet Gynecol 1983 Jul 15;146(6):696-707.

  77. Perry W, Wiseman RA, Cullen NM. Combined oral estradiol valerate-norethisterone treatment over three years in postmenopausal women. 1. Clinical aspects and endometrial histology. Gynecol Endocrinol 1998 Apr;12(2):109-22.

  78. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994 May;83(5 Pt 1):686-92.

  79. Nand SL, Webster MA, Baber R, O’Connor V. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. The Ogen/Provera Study Group. Obstet Gynecol 1998 May;91(5 Pt 1):678-84.

  80. Magos AL, Brincat M, Studd JW, Wardle P, Schlesinger P, O’Dowd T. Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1985 Apr;65(4):496-9.

  81. Coleman DV, Poznansky JJ. Review of cervical smears from 76 women with invasive cervical cancer: cytological findings and medicolegal implications. Cytopathology 2006 Jun;17(3):127-36.

  82. Giard RW, Blok P. [Cervical smears unsuitable for exclusion of cervical carcinoma]. Ned Tijdschr Geneeskd 2000 Jan 8;144(2):86-7.

  83. Giard RW. False-negative rate of cervical cytology: sense and sensitivity. Diagn Cytopathol 2001 Nov;25(5):275-7.

  84. Mitchell H, Medley G, Giles G. Cervical cancers diagnosed after negative results on cervical cytology: perspective in the 1980s. BMJ 1990 Jun 23;300(6740):1622-6.

  85. Van den BT, Vandendael A, Wranz PA, Lombard CJ. Cervical cytology in menopausal women at high risk for endometrial disease. Eur J Cancer Prev 1998 Apr;7(2):149-52.

  86. Dutch College of General Practitioners. NHG Practice Guideline ”Vaginal bleeding”. http://nhg.artsennet.nl/upload/104/guidelines2/E28.htm.  2004. (OBS! Linket er ikke længere aktivt).

  87. Gull B, Karlsson B, Milsom I, Granberg S. Can ultrasound replace dilation and curettage? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer. Am J Obstet Gynecol 2003 Feb;188(2):401-8.

  88. Farrell T, Jones N, Owen P, Baird A. The significance of an ’insufficient’ Pipelle sample in the investigation of post-menopausal bleeding. Acta Obstet Gynecol Scand 1999 Oct;78(9):810-2.